- Facing pharmacy trends for the remainder of the year
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Americans more likely than others to prefer generics, study finds
- State of the market: Are generic drugs approaching their peak?
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
ST. LOUIS K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said Wednesday.
K-V announced the establishment of Nesher Pharmaceuticals, appointing as its president Mark Hartman, who has had several positions in generic drug companies.
“Mark brings recognized depth and breadth of generic industry experience and leadership to K-V,” K-V interim president and CEO Greg Divis said. “We are excited to have Mark join our organization and look forward to him leading the introduction of Nesher Pharmaceuticals Inc., K-V’s new generic subsidiary.”